Lunai Bioworks(LNAI.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Lunai Bioworks
LNAI.US
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.
1.951 T
LNAI.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons | LNAI Stock News

    Lunai Bioworks (NASDAQ: LNAI) has launched Sentinel™, an AI safeguard designed to prevent the generation of novel chemical weapons by embedding directly into large language models. This transformer-based biosecurity layer utilizes Lunai's proprietary datasets to screen molecular outputs in real-time, addressing the dual-use risks of AI in chemistry and biology. The launch positions Lunai at the forefront of AI safety infrastructure, as it aims to ensure that powerful generative systems are used for innovation rather than misuse. Sentinel is part of Lunai's broader biodefense strategy, which includes programs for identifying and countering emerging chemical threats.

    StockTitan·
    US
    LNAI
    -2.04%
    StockTitan·
    US
    LNAI
    -2.04%

    Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery | LNAI Stock News

    Lunai Bioworks (NASDAQ: LNAI) has launched a new commercial drug discovery program targeting Alcohol Use Disorder (AUD) after achieving key milestones in its NIH-funded AI initiative. The program aims to develop precision therapies for AUD, which affects around 30 million people in the U.S. and is largely untreated. The initiative highlights the unmet need in AUD treatment and the potential for partnerships and funding opportunities. Lunai's CEO emphasized the importance of addressing the biological complexity of AUD to create effective therapies.

    StockTitan·
    US
    LNAI
    -2.04%
    StockTitan·
    US
    LNAI
    -2.04%

    Lunai Bioworks Unveils AI-Driven Platform to De-Risk Drug Discovery in Complex Diseases

    Lunai Bioworks Inc. has launched an AI-driven platform, Augusta, aimed at enhancing drug discovery for complex neurological disorders. The platform utilizes advanced AI to analyze patient data, identify distinct sub-diseases, and match them with effective therapies. This approach seeks to validate drug candidates in living systems, thereby reducing failure rates and expediting development timelines for pharmaceutical partners. The presentation emphasizes a shift towards "biology-first" AI strategies in biopharma, particularly for conditions like Parkinson's disease and epilepsy.

    Reuters·
    US
    RENB
    0.00%
    US
    LNAI
    -2.04%
    Reuters·
    US
    RENB
    0.00%
    US
    LNAI
    -2.04%

    Lunai Bioworks discovers 3 Parkinson's subtypes, targets for $13B market. Exciting progress in precision therapeutics.

    Today, in Sacramento, California, Lunai Bioworks (NASDAQ: LNAI), a biotechnology company utilizing AI to develop precision therapeutics, revealed the discovery of three significant subtypes of Parkinson's disease. They have also prioritized drug targets that show promise for treatment.

    Unusual Whales·
    US
    RENB
    0.00%
    US
    LNAI
    -2.04%
    Unusual Whales·
    US
    RENB
    0.00%
    US
    LNAI
    -2.04%

    Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market | LNAI Stock News

    Lunai Bioworks (NASDAQ: LNAI) has identified three Parkinson's disease subtypes and prioritized drug targets using its Augusta Platform. This discovery aims to accelerate proof-of-concept programs and strategic partnerships in a $13 billion market. The analysis, integrating data from the Parkinson's Progression Markers Initiative, revealed subtypes linked to rapid progression, cognitive decline, and functional impairment. Lunai Bioworks is advancing experimental validation and exploring co-development opportunities to improve trial success rates and accelerate development timelines.

    StockTitan·
    US
    LNAI
    -2.04%
    StockTitan·
    US
    LNAI
    -2.04%
    © 2026 Longbridge｜Disclaimer